GlycoMimetics Q1 cash $65M; uproleselan Phase 3 trial on track for H1 2024 survival trigger

CRESCENT BIOPHARMA, INC.

2023-Q1 EPS reported -$0.17

Cash and equivalents $65.0M as of March 31, 2023, up from $47.9M at Dec 31, 2022; raised $28.7M via ATM.
R&D expenses fell to $5.4M from $9.6M YoY on lower clinical trial costs after Phase 3 enrollment completed.
Phase 3 uproleselan study continues; final overall survival event trigger projected within first half of 2024.
Cash runway expected to fund operations into late Q4 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRESCENT BIOPHARMA, INC. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 3, 2023, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-007746

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.